Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 24, Issue 5, Pages 1253-1261
Publisher
Oxford University Press (OUP)
Online
2012-12-12
DOI
10.1093/annonc/mds622
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
- (2012) Y. Y. Janjigian et al. ANNALS OF ONCOLOGY
- Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas
- (2012) H. H. Yoon et al. CLINICAL CANCER RESEARCH
- Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer
- (2012) M. Terashima et al. CLINICAL CANCER RESEARCH
- Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment
- (2011) Judith Maresch et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH)
- (2011) James E. Boers et al. HISTOPATHOLOGY
- Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
- (2011) Marc Ychou et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
- (2011) Angelo Di Leo et al. LANCET ONCOLOGY
- Alteration of Topoisomerase II–Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy
- (2010) Michael F. Press et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
- (2010) Josef Rüschoff et al. VIRCHOWS ARCHIV
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- (2009) Carolyn D. Seib et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)
- (2008) Hiroaki Nitta et al. Diagnostic Pathology
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
- Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial
- (2008) John M.S. Bartlett et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials
- (2007) Alessandra Gennari et al. JNCI-Journal of the National Cancer Institute
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started